InMode Ltd. (INMD)
Healthcare
- Fundamental
- 4
- Sentiment
- 3
- Technical
- 2
Do Nothing: technicalScore 2 (below the required >=3) — price below the SMA20/SMA50 with negative MACD, RSI 36, ADX 14 and a distribution day on elevated volume; no actionable bullish setup, and any pullback limit would be countertrend.
Company overview
InMode Ltd. is a medical technology company specializing in aesthetic medical devices, offering both minimally invasive and non-surgical solutions. The company's products utilize radiofrequency technologies for procedures such as liposuction, skin firming, and body sculpting. InMode also provides non-invasive devices for hair removal, skin revitalization, and other cosmetic treatments.
Fundamental
goodInMode maintains strong profitability and liquidity, but faces growth challenges and geopolitical risks.
FundamentalScore 4/5: cash-rich, still-profitable aesthetics device maker trading at low EV multiples (EV/EBITDA ~4.65) and high free-cash-flow yield (~10.45%). Main concerns are multi-year revenue/earnings decline from the 2023 peak, a large inventory build, and SEC-disclosed geopolitical (Israel) and litigation risks.
Sentiment
fairSentiment is influenced by unresolved takeover bids and a recent product launch, with no clear directional shift.
Dominant catalyst: the unresolved competing-takeover process — Steel Partners' $16.75/sh cash bid topping the CEO-led $16.20 offer under special-committee review — announced, market-rewarded (shares jumped on the bid), partially priced, alongside today's Morpheus8 Cool launch; sentiment delta is determinate but flat (baseline +0.03 → scoring +0.04), retail velocity indeterminate, and the Red-Flag Screen is clean, with a law-firm securities-investigation solicitation as low-confidence overhang only. The constructive read rests on the market-rewarded announced catalysts, not on the flat delta.
Technical
weakThe stock is in a short-term downtrend with negative momentum indicators, lacking a bullish setup.
Chart is in a short-term downtrend within a larger range: price 14.58 sits below the SMA20 (14.90) and SMA50 (15.08), and below EMA9 (14.82), EMA21 (14.90) and the daily VWAP (14.63), while holding just above the SMA200 (14.40). Momentum is negative: MACD line -0.07 below signal -0.05 and below zero with a negative histogram, RSI14 36.27, Williams %R -71.26, and ADX14 14.02 confirming no directional strength. The Sep 16 session (-1.55%) was a distribution day on elevated volume (~958K vs ~586K the prior session). No oversold extreme and no reversal confirmation, so there is no actionable bullish setup; a pullback limit would additionally be countertrend (price below the SMA50 with MACD < 0). Score 2, below the >=3 threshold for a bullish entry.
You’re looking at 2026-09-16 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

